Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers

Anne Marit Rykkelid, Priyanshu Manojkumar Sinha, Charlemagne Asonganyi Folefac, Michael R. Horsman, Brita Singers Sørensen, Tine Merete Søland, Olaf Joseph Franciscus Schreurs, Eirik Malinen, Nina Frederike J. Edin*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


Combining radiation therapy with immunotherapy is a strategy to improve both treatments. The purpose of this study was to compare responses for two syngeneic head and neck cancer (HNC) tumor models in mice following X-ray or proton irradiation with or without immune checkpoint inhibition (ICI). MOC1 (immunogenic) and MOC2 (less immunogenic) tumors were inoculated in the right hind leg of each mouse (C57BL/6J, n = 398). Mice were injected with anti-PDL1 (10 mg/kg, twice weekly for 2 weeks), and tumors were treated with single-dose irradiation (5–30 Gy) with X-rays or protons. MOC2 tumors grew faster and were more radioresistant than MOC1 tumors, and all mice with MOC2 tumors developed metastases. Irradiation reduced the tumor volume in a dose-dependent manner. ICI alone reduced the tumor volume for MOC1 with 20% compared to controls, while no reduction was seen for MOC2. For MOC1, there was a clear treatment synergy when combining irradiation with ICI for radiation doses above 5 Gy and there was a tendency for X-rays being slightly more biologically effective compared to protons. For MOC2, there was a tendency of protons being more effective than X-rays, but both radiation types showed a small synergy when combined with ICI. Although the responses and magnitudes of the therapeutic effect varied, the optimal radiation dose for maximal synergy appeared to be in the order of 10–15 Gy, regardless of tumor model.

TidsskriftScientific Reports
Antal sider8
StatusUdgivet - 2024


Dyk ned i forskningsemnerne om 'Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers'. Sammen danner de et unikt fingeraftryk.